Open-label phase II study in 26 adults and adolescents with EPP or XLP: bitopertin 20 mg and 60 mg reduced protoporphyrin IX from baseline by a mean 31.7% and 57.7%. No serious adverse events; dizziness was most common (64% and 67%).
RCTn = 26
Ross et al. An open-label phase II study of bitopertin in adults and adolescents with erythropoietic protoporphyria or X-linked protoporphyria